De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Viveve Medical Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	6.8yrs
Gemiddelde ambtstermijn bestuur	6.1yrs

Recente managementupdates

Recent updates

Viveve to get US patent for technology to treat female stress urinary incontinence

Oct 04

Viveve jumps 19% after FDA clearance for expansion of manufacturing treatment tips

Dec 03

CEO

Viveve Medical heeft geen CEO, of we hebben geen gegevens over hen.

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jim Robbins	Senior VP of Finance & Administration and Principal Accounting & Financial Officer	7.3yrs	US$701.05k	geen gegevens
Deborah Jorn	Senior Advisor to the CEO & Director	6.4yrs	US$208.88k	geen gegevens
Martin Kerber	Vice President of Research	6.8yrs	geen gegevens	geen gegevens
Jeannie Swindle	Senior Director of Corporate Communications	no data	geen gegevens	geen gegevens
Jeff Sinclair	Vice President of International Sales	no data	geen gegevens	geen gegevens
Gary Kaiser	Vice President of Global Marketing	no data	geen gegevens	geen gegevens
Lori McMillan	Vice President of Human Resources	7.4yrs	geen gegevens	geen gegevens
Suzon Lommel	Senior Vice President of Regulatory & Quality Affairs	6.8yrs	geen gegevens	geen gegevens

6.8yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van VIVE is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Deborah Jorn	Senior Advisor to the CEO & Director	8.4yrs	US$208.88k	geen gegevens
Steven Basta	Independent Chairman of the Board	6.1yrs	US$469.44k	geen gegevens
Alan Wein	Member of Clinical Advisory Board in Urinary Incontinence	no data	geen gegevens	geen gegevens
Sharon Presnell	Independent Director	4yrs	US$196.13k	geen gegevens
Roger Dmochowski	Member of Clinical Advisory Board in Urinary Incontinence	no data	geen gegevens	geen gegevens
Mickey Karram	Member of Clinical Advisory Board in Urinary Incontinence	no data	geen gegevens	geen gegevens
Kathleen Kobashi	Member of Clinical Advisory Board in Urinary Incontinence	no data	geen gegevens	geen gegevens
Scott MacDiarmid	Member of Clinical Advisory Board in Urinary Incontinence	no data	geen gegevens	geen gegevens
Eric Rovner	Member of Clinical Advisory Board in Urinary Incontinence	no data	geen gegevens	geen gegevens

6.1yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van VIVE wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.1 jaar).

Viveve Medical Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Viveve Medical, Inc. Appoints Sharon Collins Presnell to the Board of Directors and Its Audit Committee, Effective October 28, 2020

Recent updates

InMode Ltd. (NasdaqGS:INMD) acquired Intellectual Property Assets of Viveve Medical Inc.

Viveve Medical, Inc.(OTCPK:VIVE) dropped from NASDAQ Composite Index

Viveve Medical, Inc. Intends to File A Form 15 with the Securities and Exchange Commission

Viveve Medical, Inc. Announces Completion of Pivotal US Pursuit Trial for Female Stress Urinary Incontinence

Viveve Medical Receives Notice from the Listing Qualifications Staff of Nasdaq

Viveve Medical Receives a Non-Compliance Letter from Nasdaq

Price target decreased to US$4.68

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Viveve Medical, Inc. announced that it has received $0.014675 million in funding

Viveve Medical, Inc. Announces Notice of Allowance for Second U.S. Method Patent for Treating Female Stress Urinary Incontinence

Viveve to get US patent for technology to treat female stress urinary incontinence

Viveve Medical, Inc. Launches Rebranding Initiative to Reflect Focus on Treatment of Female Stress Urinary Incontinence in Anticipation of U.S. Pivotal Pursuit Trial Readout

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Viveve Medical, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Viveve Medical receives patent for dual-energy technology in Taiwan

Viveve Medical Receives a Letter from Nasdaq Regarding Minimum Bid Price Requirement

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Price target decreased to US$6.88

Consensus revenue estimates fall by 15%

Price target decreased to US$9.63

Viveve Medical, Inc. Announces Initiation of Pivotal U.S. Pursuit Trial in Stress Urinary Incontinence

Viveve Medical, Inc. has completed a Composite Units Offering in the amount of $23.999988 million.

Viveve under pressure after upsizes capital raise, prices offering at $3.40

Viveve Regains Compliance with Nasdaq Continued Listing Rules

Viveve regains compliance with Nasdaq

Viveve Announces FDA 510K Approval to Expand Manufacturing of Treatment Tips

Viveve jumps 19% after FDA clearance for expansion of manufacturing treatment tips

Viveve Medical, Inc. to Report Q3, 2020 Results on Nov 12, 2020

Viveve Medical, Inc. Appoints Sharon Collins Presnell to the Board of Directors and Its Audit Committee, Effective October 28, 2020

Viveve Medical, Inc. to Report Q2, 2020 Results on Aug 13, 2020

Viveve Medical, Inc. announced that it expects to receive $10 million in funding from Lincoln Park Capital, LLC

CEO

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd